CO2022006909A2 - Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso - Google Patents

Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso

Info

Publication number
CO2022006909A2
CO2022006909A2 CONC2022/0006909A CO2022006909A CO2022006909A2 CO 2022006909 A2 CO2022006909 A2 CO 2022006909A2 CO 2022006909 A CO2022006909 A CO 2022006909A CO 2022006909 A2 CO2022006909 A2 CO 2022006909A2
Authority
CO
Colombia
Prior art keywords
generation
methods
fever virus
yellow fever
virus antibodies
Prior art date
Application number
CONC2022/0006909A
Other languages
English (en)
Inventor
Laura Walker
Anna Wec
Original Assignee
Mabloc Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mabloc Llc filed Critical Mabloc Llc
Publication of CO2022006909A2 publication Critical patent/CO2022006909A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se proporcionan anticuerpos y fragmentos de unión al antígeno de los mismos específicos para la proteína E de YFV y con potencia neutralizante contra YFV. Estos anticuerpos y fragmentos de unión al antígeno son útiles en el tratamiento de YFV.
CONC2022/0006909A 2019-11-25 2022-05-25 Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso CO2022006909A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962940049P 2019-11-25 2019-11-25
PCT/US2020/062084 WO2021108448A1 (en) 2019-11-25 2020-11-24 Anti-yellow fever virus antibodies, and methods of their generation and use

Publications (1)

Publication Number Publication Date
CO2022006909A2 true CO2022006909A2 (es) 2022-08-19

Family

ID=74046131

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0006909A CO2022006909A2 (es) 2019-11-25 2022-05-25 Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso

Country Status (14)

Country Link
US (2) US11479598B2 (es)
EP (1) EP4065601A1 (es)
JP (1) JP2023503347A (es)
KR (1) KR20220111289A (es)
CN (1) CN114867744A (es)
AU (1) AU2020394408A1 (es)
BR (1) BR112022010179A2 (es)
CA (1) CA3162718A1 (es)
CO (1) CO2022006909A2 (es)
EC (1) ECSP22041860A (es)
IL (1) IL293282A (es)
PE (1) PE20221865A1 (es)
WO (1) WO2021108448A1 (es)
ZA (1) ZA202205927B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293282A (en) 2019-11-25 2022-07-01 Mabloc Llc Yellow fever antiviral antibodies and methods of making and using them
CN113683690B (zh) * 2021-08-19 2023-05-23 中国科学院微生物研究所 针对黄热病毒ns1蛋白的抗体及其应用
WO2023034566A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Anti-dll3 antibodies and uses thereof
TW202328176A (zh) * 2021-09-07 2023-07-16 美商馬布羅克公司 抗-sars-cov-2抗體組成物及其用途
WO2024039298A1 (en) * 2022-08-17 2024-02-22 Agency For Science, Technology And Research Anti-yellow fever virus antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2010081856A1 (en) 2009-01-14 2010-07-22 Ablynx Nv Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
PT2438087T (pt) 2009-06-05 2017-08-04 Ablynx Nv Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório
CN110343173B (zh) * 2018-04-04 2021-05-04 中国科学院微生物研究所 一种高功能活性的黄热病毒人源单克隆抗体及其应用
CN110343174B (zh) * 2018-04-04 2021-05-04 中国科学院微生物研究所 一种高亲和力的黄热病毒人源单克隆抗体及其应用
BR112020020787A2 (pt) * 2018-04-11 2021-02-02 Tychan Pte. Ltd. métodos e composições para o tratamento de febre amarela
IL293282A (en) 2019-11-25 2022-07-01 Mabloc Llc Yellow fever antiviral antibodies and methods of making and using them

Also Published As

Publication number Publication date
WO2021108448A1 (en) 2021-06-03
AU2020394408A1 (en) 2022-06-09
ECSP22041860A (es) 2022-09-30
JP2023503347A (ja) 2023-01-27
US20210253675A1 (en) 2021-08-19
BR112022010179A2 (pt) 2022-08-30
EP4065601A1 (en) 2022-10-05
CN114867744A (zh) 2022-08-05
CA3162718A1 (en) 2021-06-03
PE20221865A1 (es) 2022-12-02
ZA202205927B (en) 2023-11-29
KR20220111289A (ko) 2022-08-09
IL293282A (en) 2022-07-01
US11479598B2 (en) 2022-10-25
US20230203135A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
CO2022006909A2 (es) Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso
PH12020550650A1 (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
CO2019012210A2 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
CL2023000895A1 (es) Receptores quiméricos de dll3 y métodos para su uso
UY36539A (es) Proteínas de unión a icos
CR20180142A (es) ANTICUERPOS ANTI-FAP Y MÉTODOS DE USO(Divisional Exp: 2013-0038)
CO2018003852A2 (es) Proteínas de unión a antigeno que activan el receptor de leptina
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
BR112021015477A2 (pt) Anticorpos anti-cd228 e conjugados anticorpo-fármaco
EA202091888A1 (ru) Вариабельные домены антител, нацеленные на рецептор nkg2d
CO2018011663A2 (es) Nticuerpos anti-basigin humanizados y uso de los mismos
CL2022001554A1 (es) Anticuerpos anti-mertk y métodos de uso de los mismos
AR117565A1 (es) Agentes de unión a c3 y método de uso de los mismos
CL2021001615A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
CO2022006014A2 (es) Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas
UY37752A (es) Proteínas de unión al antígeno anti-jagged1
CL2023001492A1 (es) Anticuerpos anti-ly6g6d y métodos de uso.
CL2019002642A1 (es) Anticuerpos de hantavirus andes y métodos de uso de los mismos.
PE20171734A1 (es) Anticuerpos monoclonales especificos del antigeno m del virus metapneumovirus humano (hmpv) y su uso en un metodo de diagnostico
AR115992A2 (es) Proteínas de unión a antígeno que activan el receptor de leptina
EA202090240A1 (ru) Усовершенствованная молекула полипептида с двойной специфичностью
EA202092941A1 (ru) Конъюгаты камптотецина